DGAP-News: MOLOGEN AG will next clinically investigate the efficacy of MGN1703 in lung cancer
(firmenpresse) - DGAP-News: MOLOGEN AG / Key word(s): Miscellaneous
MOLOGEN AG will next clinically investigate the efficacy of MGN1703 in
lung cancer
06.06.2011 / 08:01
---------------------------------------------------------------------
- Application for pivotal phase II/III clinical trial in preparation
- Expansion of the product pipeline with further blockbuster candidate
- Lung cancer is one of the most prevalent forms of cancer worldwide
Berlin, 6 June 2011 - MOLOGEN AG will now clinically investigate its DNA
immunomodulator MGN1703 in the treatment of advanced lung cancer. With this
MOLOGEN will be expanding its attractive product pipeline by one more
blockbuster candidate. Work is currently underway on the application for
the pivotal phase II/III clinical trial.
The basis for the active principle which will be applied in the clinical
trial is provided by the company's own dSLIM(R) platform technology. This
technology, comprehensively patented, offers diverse application
possibilities in the treatment of cancer. Here, the unique structure of the
immunomodulator, which is exclusively composed of natural DNA components,
is the decisive differentiator to comparable approaches from competitors.
To date, no technology from the competition has been able to feature the
extremely good compatibility while concurrently activating the immune
system in such a broad and efficacious way. With the effective decision to
clinically investigate lung cancer as further indication, MOLOGEN AG is
actively pursuing the path to further implement the potential of the
dSLIM(R) technology consistently and specifically.
Dr. Matthias Schroff, Chief Executive Officer of MOLOGEN AG: 'Following our
advance to clinical phase II/III with our DNA immunomodulator MGN1703 in
colorectal cancer, we now want to proof the indications of efficacy of the
compound in further cancer indications and apply its active principle in
the treatment of lung cancer. Similar to colorectal cancer, we will
investigate the efficacy in lung cancer with a pivotal phase II/III
clinical trial. Lung cancer is one of the most prevalent forms of cancer
and non-small cell lung cancer is the most common and very aggressive type
of lung cancer. With MGN1703 we have the potential to play a prominent role
in this important market segment.'
Active principle of MGN1703 usable in numerous cancers
The first indications of the efficacy of the immunomodulator MGN1703 in the
treatment of cancer became apparent during the comprehensive pre-clinical
studies, and also from the results of the phase Ib clinical trial concluded
in 2009. The universal active principle of MGN1703 is based on the broad
activation of the immune system in a manner that is necessary for
successful treatment of cancer. Thus, MOLOGEN AG is in a position to use
MGN1703 in different cancer indications. Similar to the colorectal cancer
trial, this new clinical trial on lung cancer will be started directly in
the pivotal phase II/III. This means that the international trial will be
placebo-controlled, randomized and blinded.
During the study, the efficacy of MGN1703 in the treatment of metastatic
non-small cell lung cancer (NSCLC) will be examined. The aim of the study
is to prevent progression of the disease for longer than is possible with
existing therapy forms. Among other goals, so-called progression-free
survival is to be measured on approximately 200 patients during the study.
DNA Medicine with blockbuster potential
Lung cancer is one of the most common forms of cancer in the world. In the
EU and USA alone, about 500,000 people develop this form of cancer every
year. Within the same time period, about 460,000 people die of the disease.
The demand for more efficacious therapy options is correspondingly high.
Due to the market size, which is comparable to colorectal cancer, MGN1703
also has a blockbuster potential in the indication lung cancer.
Information for patients
Further information about the clinical study is available on the homepage
of MOLOGEN AG:
www.mologen.com/data/English/03_08_Patientinfo.
Study registers
The study is registered on www.clinicaltrials.gov and www.cancer.gov.
Hotline
A study hotline at MOLOGEN AG for MGN1703 provides information individually
and in strict confidence in accordance with medical discretion to
interested doctors and patients on:
+49 (0)800 646 1703
About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin
specializes in the research and development of innovative medicines on the
basis of DNA structures. The activities focus on numerous product
developments which are relevant to the immune system; on the one hand
vaccines against infectious diseases and on the other hand cancer
therapies. MOLOGEN AG is globally one of the few biotechnology companies
with well tolerated DNA-based cancer treatment in the clinical development
phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German
stock exchange
(ISIN DE0006637200).
Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and
biotechnology e.V. | German industrial association of biotechnology (DIB)
| Association for the Promotion of Science and Humanities in Germany |
Association of German biotechnology companies (VBU) | Association of
researching manufacturers of pharmaceuticals e.V. (VFA) | Association of
the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
INVESTOR RELATIONS:
Joerg PetraßTel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
External Investor Relations
Kirchhoff Consult AG
Janina Wismar
T: +49 - 40 - 60 91 86 - 50
F: +49 - 40 - 60 91 86 -16
janina.wismar(at)kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
End of Corporate News
---------------------------------------------------------------------
06.06.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
127508 06.06.2011
Datum: 06.06.2011 - 08:01 Uhr
Sprache: Deutsch
News-ID 34311
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG will next clinically investigate the efficacy of MGN1703 in lung cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
